Physician profile
Danny Benmoshe
NPI 1336330141
$268,336.75
in general payments reported to CMS, 2019-2025
73 companies · $59K in 2025
The $59K reported for 2025 was more than what 97% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,447 · 2020: $30K · 2021: $48K · 2022: $21K · 2023: $24K · 2024: $83K · 2025: $59K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $74K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $50K · Travel and Lodging: $24K · Food and Beverage: $12K · Consulting Fee: $5,860 · Education: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $74,257.50 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $49,805.00 |
| Travel and Lodging | $23,692.38 |
| Food and Beverage | $11,852.90 |
| Consulting Fee | $5,860.00 |
| Education | $876.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $83,141.99 | 2021-2025 | |
| Lilly USA, LLC | $70,043.45 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Abbvie INC. | $43,073.01 | 2021-2025 | Qulipta, Ubrelvy, Vraylar |
| Allergan, INC. | $34,638.48 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $19,673.08 | 2021 | |
| Biogen, INC. | $4,104.80 | 2019-2024 | Tysabri, Vumerity |
| Biohaven Pharmaceutical Holding Company LTD. | $2,290.81 | 2022 | |
| Amgen INC. | $1,154.10 | 2019-2022 | |
| Lundbeck LLC | $992.46 | 2020-2025 | Vyepti |
| Upsher-Smith Laboratories LLC | $812.84 | 2019-2022 | |
| Pfizer INC. | $699.52 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $559.86 | 2019-2024 | Austedo Xr, Austedo |
| Mdd US Operations, LLC | $526.36 | 2019-2025 | Gocovri |
| Acorda Therapeutics, INC | $368.50 | 2019-2024 | Inbrija, Ampyra |
| Neurelis, INC. | $355.91 | 2020-2025 | Valtoco |
Show all 73 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danny Benmoshe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.